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Abstract
Background: An acetominophen overdose (AOD) is the leading cause of acute liver failure (ALF) in the
UK and USA. For patients who meet the King's College Hospital criteria, (mortality risk > 85%), an
emergency orthotopic liver transplantation (OLT) is conventionally performed with subsequent life-long
immunosuppression. A new technique was developed in 1998 for AOD-induced ALF where a subtotal
hepatectomy (right hepatic trisectionectomy) and whole graft auxiliary liver transplant (WGALT) was
performed with complete withdrawal of immunosupression during the first year post-operatively.
Results: During 1998–2010, 68 patients were listed for an emergency transplantation for AOD ALF at our
institution: 28 died waiting, 16 underwent OLT and 24 a subtotal hepatectomy with WGALT. Eight OLT
(50%) and 16 WGALT remain alive (67%); actuarial survival at 5 years OLT 50%, WGALT 63%, P = 0.37.
All patients who had successful WGALT are off immunosuppression. Poor prognostic factors in the
WGALT group included higher donor age (40.4 versus 53.9, P = 0.043), requirements for a blood
transfusion (4.3 versus 7.6, P = 0.0043) and recipient weight (63.1 versus 54 kg, P = 0.036).
Conclusion: Although OLT remains standard practice for AOD-induced ALF, life-long immunosuppression
is required. A favourable survival rate using a subtotal hepatectomy and WGALT has been demonstrated,
and importantly, all successful patients have undergone complete immunosuppression withdrawal. This
technique is advocated for patients who have acetominophen hepatotoxicity requiring liver transplantation.
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Introduction
Acute liver failure (ALF), defined as the presence of hepatic
encephalopathy and coagulopathy in patients with no history of
liver disease, is the result of an abrupt loss of both hepatic meta-
bolic and immunological function, and in many cases can rapidly
progress to multi-organ failure.1 The aetiology of ALF is diverse
including viral, autoimmune and drug-related causes.1–3 An
acetominophen overdose (AOD) is the predominant cause of ALF
in the UK and USA and the overall mortality in this group is as
high as 28%.4–6 Patients with AOD-induced ALF who meet King’s
College Hospital (KCH) criteria have amortality risk of more than
85% without emergency liver transplantation.2,5,7 The overall
5-year survival rate after an orthotopic liver transplantation
(OLT) for AOD-induced ALF is reported to be up to 67%.4,6
However, OLT results in the need for life-long immunosuppres-
sion and in the AOD patient group there are concerns about
psychological and/or psychiatric problems that can make adher-
ence to treatment unmanageable, even with full social support.8
To minimize the risks of poor compliance and also reduce the
long-term risks of immunosuppression associated with OLT, an
auxiliary liver transplantation (ALT) may be considered as an
alternative. With AOD-induced ALF, time and appropriate sup-
portive therapy give the potential for full hepatic recovery. With
this notion, an auxiliary liver transplant can be used to bridge the
gap to give the native liver time to recover. Once sufficient native
liver function has returned, immunosuppression can be with-
drawn and the transplanted liver allowed to atrophy.
This manuscript was presented at the 10th World IHPBA Congress, Paris,
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Our institution performsmore than 250 solid organ transplants
and over 300 liver resections annually, and has the largest reported
experience worldwide with hepatic trisectionectomy.9,10 The
senior author developed a new technique in 1998 in which a right
hepatic trisectionectomy was performed as a subtotal hepatec-
tomy combined with whole graft auxiliary liver transplant
(WGALT) for AOD-induced ALF, and initial results were reported
in 2008.11 In this study, the largest reported series is presented and
the long-term results are demonstrated.
Methods
During January 1998 to July 2010, 24 patients underwent a sub-
total hepatectomy with WGALT for AOD at our institution.
Patients referred for further management after AOD from other
UK hepatology and gastroenterology centres were commenced on
medical therapy prior to transfer. Patients were listed for ‘super-
urgent’ liver transplantation based on KCH criteria for AOD.
Surgical principles
The surgical principles and techniques have been described in
detail previously.11 In summary, after a right hepatic trisectionec-
tomy (resection of liver segments 4, 5, 6, 7 and 8), a whole graft is
implanted in an orthotopic manner. Caval anastomosis is per-
formed using a donor upper end to recipient side cavo-cavostomy,
with suture closure of the lower donor IVC. The donor portal vein
is anastomosed end to end to the recipient right portal vein.
Arterial anastomosis was initially to the recipient right hepatic
artery but after early hepatic artery thrombosis in case 3 it has
been performed using a conduit from the right common iliac or
external iliac artery. A Roux-en-Y hepaticojejunostomy to the
donor CBD/CHD is performed to avoid any risk of stricturing the
recipient biliary tree.
Donor liver policies
According to our policy for super-urgent OLT, there was no donor
selection bias in that the first liver offered nationally was accepted
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Figure 1 Flow chart depicting the course for the 68 acetominophen overdose (AOD) patients admitted to our institution. In total, 24 had
whole graft auxiliary transplant (WGALT)
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in all cases. All re-transplants (for WGALT failure) were per-
formed as OLT with resection of the remaining native liver
remnant.
Withdrawal of immunosuppression
Immunosuppression consisted of cyclosporin or tacrolimus com-
bined with corticosteroids and azathioprine or mycophenolate
mofetil, according to our standard protocol for OLT at that time.
Corticosteriods were withdrawn within 12 weeks of transplanta-
tion in all patients. At 3 months post-operatively, a hepatic imino-
diacetic acid (HIDA) and computerized tomography (CT)
scan were used to judge recovery in the native liver. At this stage,
a full discussion with each patient was carried out to obtain
consent for immunosuppression withdrawal and azathioprine/
mycophenolate mofetil was discontinued. The calcineurin inhibi-
tors were reduced by one-third dose every month. The aim was to
discontinue all immunosuppression by 6 to 12 months.11 Liver
function tests and clinic reviews were the only monitoring during
immunosuppressionwithdrawal.ACTwas performed at 6months
to confirm atrophy of the graft and hypertrophy of the native liver.
All patients were followed up closely during immunosuppression
withdrawal and on an annual basis once immunosuppression was
completely withdrawn.
Data analysis
Patient and donor characteristics analysed included listing pH,
prothrombin time (PT), serum creatinine, recipient/donor
Table 1 Summary of recipient and donor data for all 24 WGALT patients with outcomes
Patient
No.
Age
(years)
Gender Weight
(kg)
Listing
PSE
Listing
pH
Listing
PT (s)
Listing
creatinine
(mmol/l)
Donor age Donor
weight
(kg)
Donor-
recipient
weight
ratio
1 37 F 60 4 7.20 33.20a 235.00 30 54.00 0.9
2 22 M 56 4 6.99 54.10 255.00 69 58.00 1.03
3 39 F 55 4 7.29 18.60a 419.00 11 35.00 0.6
4 37 F 60 4 7.14 130.00 288.00 46 55.00 0.9
5 18 F 60 4 7.12 63.10 182.00 37 75.00 1.2
6 25 F 58 4 7.15 66.00 282.00 49 54.00 0.9
7 29 M 90 4 7.10 28.60a 520.00 68 55.00 0.6
8 41 F 65 4 6.94 102.00 391.00 54 70.00 1.07
9 41 M 71 4 7.17 105.00 337.00 37 65.00 0.9
10 34 M 58 4 7.12 105.00 329.00 58 65.00 1.1
11 48 F 49 4 6.90 151.00 183.00 43 60.00 1.2
12 20 F 54 4 7.22 200.00 330.00 62 60.00 1.1
13 25 F 67 4 7.1 210.00 235.00 54 78 1.1
14 38 F 70 4 7.29 31 153.00 43 64 0.91
15 35 M 75 4 7.18 91 197.00 35 50 0.66
16 19 F 50 4 7.38 125 114.00 49 63 1.26
17 29 M 90 3 7.22 85 282.00 27 54 0.6
18 50 M 65 4 7.3 94 291.00 60 60 0.92
19 29 M 70 4 7.36 193 150.00 21 75 1.07
20 19 F 75 4 7.3 114 173.00 40 65 0.86
21 32 M 70 3 7.4 109 640 26 55 0.79
22 32 F 70 3 7.35 61 312 47 66 0.94
23 24 F 65 3 7.09 193a 77a 61 52 0.95
24 34 M 90 4 7.17 40 253 36 76 0.84
aDenotes supported (CVVH, blood products).
PSE, portosystemic encephalopathy; creatinine 88.4 umol/l = 1 mg/dl; Op, during surgery; HAT, hepatic artery thrombosis; PNF, primary non-function,
HV thrombus, hepatic vein thrombus; ReTx, re-transplant; CMV, cytomegalovirus; CVVH, continuous veno-veno-haemofiltration; DCD, donation after
cardiac death; POD, post-operative day; Normal values; pH 7.35–7.45, PT 10–14 seconds; creatinine, 60–120 mmol/l.
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weight, cold ischaemia time (CIT), blood product requirement
(up to 48 h post surgery), immunosuppression withdrawal and
survival.
Statistical analysis
SPSS version 17.0 (SPSS Inc., Chicago, IL) was used to calculate
means and standard deviations, using the independent t-test and
Mann–WhitneyU-test for comparison. The significance was set at
P < 0.05. Survival curves were calculated using the Kaplan–Meier
method.
Results
Patients
During January 1998 to July 2010, 207 patients received a liver
transplant for ALF and 40 of these, were for AOD. There were a
further 28 deaths in AOD patients awaiting a liver transplant. Of
the 40 AOD patients, 24 received a WGALT and 16 underwent
OLT (Fig. 1). Patient selection for WGALT depended on the
on-call surgeon’s preference and enthusiasm for this novel proce-
dure as not all surgeons in our unit had embraced the concept,
with the senior author performing 23 of the 24 WGALT proce-
dures. There was no bias in patient selection for the procedure.
In the OLT group there were 12 females and 4 males, aged 18 to
52 years (mean 37). In the WGALT group there were 14 females
and 10 males, aged 18 to 50 years (mean 31.5). Table 1 shows
patient and donor factors along with outcomes after WGALT.
There was little variation between patients selected for WGALT
over OLT, as seen in Table 2. APACHE scores between the two
groups were not statistically different. A higher donor weight was
the only significant finding in the OLT group.
Preservation
time (min)
Op blood
+48 h
(units)
Op FFP
+48 h
(units)
Op
platelets
+48 h
(units)
Survival
To Dec 2011
Outcome Comments
440 6 18 8 167 months Alive 1 readmission; no rejection
820 6 18 16 1 POD Dead Lung injury and cardiac failure
390 4 6 24 157 months Alive HAT 12 days;
Graft hepatectomy 4 weeks
525 3 18 16 157 months Alive No readmission
800 5 12 18 144 months Alive Percutaneous drainage of liver abscess
510 5 12 8 140 months Alive Graft hepatectomy for abscess 8 months after transplant
552 6 17 24 10 POD Dead PNF; OLT regraft
540 4 10 10 7 POD Dead PNF; OLT regraft
450 1 10 0 116 months Alive No readmission
515 4 16 16 112 months Alive No readmission
300 4 12 8 5 POD Dead Sudden intracranial haemorrhage
499 4 16 12 105 months Alive HV thrombus – ReTx OLT
472 2 10 8 84 months Alive CMV+; no readmission
180 9 18 32 4 POD Dead Post op bleeding – relook x 3
Septic, cardiac arrest
592 11 6 24 70 months Alive Worsening liver function secondary to alcohol
566 6 13 7 62 months Alive PE and Empyema 1 year post ALT
418 1 16 2 59 months Alive Bile leak, poor PV flow – jump graft. Tx hepatectomy at 6/52
for sepsis
445 18 19 6 60 POD Dead Bile leak. Sepsis, GI bleeding, CVVH, Intubated
205 2 6 2 23 months Dead DCD, native biliary strictures
Death from progression of Hep C
544 6 4 8 8 POD Dead Cerebral oedema, tonsillar herniation
480 3 12 2 43 months Alive Non compliant with follow up
277 4 8 2 39 months Alive Intracranial bleed, Left sided deficit. Thrombosed conduit,
graft infarction and graft hepatectomy at 6 weeks
420 7 12 2 28 months Alive No readmission
3905 5 6 2 21 months Alive No readmission
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Survival
Currently, 16 of 24 patients remain alive after WGALT. The 1-year
survival rate was 71%.Of the 8 patients that died, 6 died within 10
post-operative days, one died at 60 days and another at 23 months
after WGALT: the overall survival was 67%. Three patients
required a re-graft in the form of OLT (2 primary non-function –
died and 1 hepatic vein thrombosis – alive) giving a re-transplant
rate of 12.5%. Thus 15 of the 24 patients (63%) remain alive with
a native liver remnant. The actuarial 1-, 3- and 5-year survival
rates for successful WGALT patients (n = 15) was 70%, 65% and
65%, respectively (Fig. 2). In the OLT group, there are 8 remaining
survivors (50%) with an actuarial 1-, 3- and 5-year survival rates
of 69%, 63% and 50%, respectively. Of the eight patients that died,
there was one on-table death after reperfusion, three deaths in the
ICU, one owing to cerebral oedema, two due to sepsis and multi-
organ failure, one patient developed hepatic artery thrombosis
and developed sepsis (patient was at a different institution), one
patient developed post-transplant lymoproliferative disorder and
died 2 years after transplant, and two deaths were as a result of
chronic rejection related to poor compliance. Of the survivors,
three developed renal impairment, two of which remain chronic.
There were no regrafts performed in the OLT group (0%). There
was no significant difference in survival between the OLT and
WGALT groups, P = 0.43 (log-rank test).
Withdrawal of immunosuppresion
Immunosuppression withdrawal was successful in all patients
who survived without re-transplantation (a total of 15 patients).
During immunosuppression withdrawal,minor elevations in liver
enzymes were noted, but in the absence of systemic symptoms.
Liver function tests normalized within 3 months of immunosup-
Table 2 Comparison of factors between patients who underwent whole graft auxiliary transplant (WGALT) versus those who underwent
orthotopic liver transplantation (OLT)
WGALT (n = 24) OLT
(n = 16)
P
Recipient age 31.1 (9.1) 29.4 (9.8) 0.588a
Donor age 44.3 (15.1) 45.4 (15.4) 0.817a
Recipient weight (kg) 66.4 (11.7) 65.7 (9.7) 0.847a
Donor weight (kg) 61.0 (9.8) 69.1 (10.3) 0.019a
Weight aatio 0.93 (0.19) 1.06 (0.18) 0.036a
Listing pH 7.19 (0.13) 7.23 (0.07) 0.215b
Listing PT 100.1 (57.1) 128.6 (26.0) 0.334a
Listing creatinine (mmol/l) 276.2 (127.2) 273.9 (83.7) 0.911a
Preservation time (min) 472 (150) 583 (169) 0.825a
Blood (units) 5.3 (3.6) 7.7 (7.0) 0.338b
FFP (units) 12.3 (4.7) 16.3 (8.5) 0.166b
Platelets (units) 10.7 (8.8) 13.7 (8.3) 0.214b
aIndependent t-test statistic.
bMann– Whitney U-test statistic.
Number at Risk
WGALT 24 16 16 16
OLT 16 8 8 8
Figure 2 Kaplan–Meier survival curve for 24 patients who underwent
whole graft auxiliary transplant (WGALT) compared with 16 who had
orthotopic liver transplantation (OLT). WGALT survival (green) dem-
onstrates better survival than the OLT (blue) group
224 HPB
HPB 2014, 16, 220–228 © 2013 International Hepato-Pancreato-Biliary Association
pression cessation. In 4 patients, late WGALT graft abscesses
occurred which presented with sepsis. Two patients were treated
by percutaneous drainage and 2 required WGALT hepatectomy.
Native liver regeneration
In the surviving patients who had a successfulWGALT (n = 15), all
had good native liver regeneration and WGALT atrophy. Figure 3
demonstrates sequential CTs of a WGALT patient over a 2-year
period.
Recipient and donor data
Table 3 shows a comparison of the patients who survived for over
a year against those who died. Statistically significant factors upon
univariate analysis included higher donor age (40.4 versus 53.9,
P = 0.043) and blood transfusion requirements (4.3 versus 7.6,
P = 0.043). Multivariate analysis revealed recipient weight was
the only significant factor affecting outcome (63.1 versus 54 kg,
P = 0.036).
Complications
There were seven early post-operative deaths, six of which
occurred within 10 post-operative days. In summary, two patients
died as a consequence of graft primary non-function in spite of
re-transplantation by OLT; two patients died secondary to an
intracranial haemorrhage; two patients died as a result of sepsis
(at 4 and 60 post-operative days); and 1 patient died owing to
acute AOD-induced lung injury and cardiac failure.
Specifically, the following significant complications occurred.
Patient 2 died owing to acute AOD-induced lung injury and
(a) (b)
(c)
Figure 3 Computerized tomography (CT) scans showing native liver regeneration and transplant liver atrophy after withdrawal of immuno-
suppression. (a) At start of immunosuppression withdrawal (5 months post transplant in this case) with a 3-month withdrawal protocol. (b)
At 11 months post-transplant and off immunosupression (c). At 2 years (16 months after the last immunosuppression dose). The spleen has
moved down owing to the hypertrophy of the native left lobe. The right kidney has risen slightly owing to the increased space in the right
upper quadrant
Table 3 Comparison of factors between patients alive and dead at 1
year in the whole graft auxiliary transplant (WGALT) group
Alive
Mean (SD)
Dead
Mean (SD)
P
Recipient age 29.7 (7.2) 35.3 (12.2) 0.155a
Donor age 40.4 (14.6) 53.9 (12.2) 0.043a
Recipient weight (kg) 63.1 (11.2) 54 (9.8) 0.841a
Donor weight (kg) 60.7 (11.4) 61.7 (5.0) 0.825a
Weight ratio 0.92 (0.20) 0.94 (0.19) 0.897a
Listing pH 7.22 (0.10) 7.11 (0.18) 0.215b
Listing PT 107.5 (60.9) 82.1 (45.7) 0.334a
Listing creatinine (mmol/l) 274.2 (128.6) 280.9 (133.9) 0.911a
Preservation time (min) 467.6 (129.2) 483.0 (205.0) 0.825a
Blood (units) 4.3 (2.4) 7.6 (4.9) 0.043b
FFP (units) 11.6 (4.2) 14.0 (5.6) 0.211b
Platelets (units) 9.0 (7.9) 14.9 (9.8) 0.130b
aIndependent t-test.
bMann–Whitney U-test.
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cardiac failure. Patient 3 developedWGALT hepatic artery throm-
bosis at 12 days and required a graft hepatectomy at 4 weeks, with
immediate immunosupression withdrawal. After this case, the
decision was taken to to perform future WGALT (cases 5–24, case
4 having already been done) using an iliac arterial conduit (as
aortic clamping caused hemodynamic instability). Patients 7 and
8 both had primary non-function and were re-transplanted using
OLT. However, both these patients died within 10 post-operative
days. Both of these patients had received livers from older donors
(age 65 and 69 years). Patient 11 initially recovered then died from
an intracranial haemorrhage on day 5. Patient 12 developed
WGALT hepatic vein thrombosis and underwent a completion
hepatectomy and OLT on day 16. Patient 14 died from sepsis on
day 4. Patient 18 died after 2 months from sepsis, gastrointestinal
bleeding and acute tubular necrosis in spite of haemofiltration.
Patient 19 who was known to have hepatitis C as well as AOD,
received a DCD (donation after cardiac death) graft and pro-
gressed well initially, but developed abnormal liver function while
off immunosupression. He was found to have an exacerbation of
hepatitis C and alcoholism with progression to cirrhosis and died
23 months after ALT. Patient 20 was unresponsive afterWGALT. A
CT scan confirmed cerebral oedema and tonsillar herniation.
Patient 22 was noted to have a left-sided weakness once she had
been extubated and a CT scan confirmed an intracranial bleed. At
6 weeks, WGALT hepatic artery thrombosis occurred and a graft
hepatectomy was performed. All symptoms from her stroke have
now resolved.
Discussion
An acetominophen overdose (AOD) is the leading cause of acute
liver failure in the UK and USA1. The patients are usually young,
predominantly female and may have previous and ongoing psy-
chological issues.8 Although the majority will recover with
medical management, those who fulfill KCH criteria may be
listed for emergency liver transplantation. OLT has yielded good
short-term results and the long-term outcomes are less
favourable.4–6,8 Adherence to outpatient follow-up and immuno-
suppression is poor in theAODgroup comparedwith other groups
of patients who have undergoneOLT.6,8,11,12 This may relate to poor
patient selection and this remains difficult as these patients are
critically ill and usually intubated on arrival at the transplant
centre. A liver resection with auxiliary liver transplantation (ALT)
aims to maintain some native liver, and transplant a whole or
partial graft to allow temporary hepatic support. After an unspeci-
fied time, immunosuppression can be withdrawn and this is asso-
ciated with an improved quality of life compared with OLT.11
In AOD, hepatotoxicity is a direct liver injury caused by the
toxic metabolite of acetominophen. With an overdose, glucuro-
nyltranferases and sulfotransferases are saturated diverting the
drug to be metabolized by cytochrome P450 and generating
N-acetyl-p-benzo-quinoneimine (NAPQI) in amounts that can
deplete glutathione. If glutathione is not replenished, NAPQI
will begin to accumulate in the hepatocytes, leading to an
increase in levels of cytosolic calcium and ultimately loss of
membrane integrity.5 There is evidence that AOD can cause
mitochondrial dysfunction, eventually leading to an alteration of
membrane permeability and release of mitochondrial proteins
into the cell cytoplasm, and oncotic necrosis of hepatocytes.5
There is also alteration of the innate immunity of the liver as cell
death caused by toxic metabolites activates Kupffer cells and
phagocytic macrophages of the liver to release cytokines that
may activate natural killer cells. These may contribute to further
liver damage by cytotoxic activity. Inflammatory mediators,
cytokines and chemokines, recruit and accumulate neutrophils
in the liver and exacerbate the hepatic injury.5 This process leads
to development of hepatic necrosis which can be fatal and is well
circumscribed by the term ‘toxic liver syndrome’. This is charac-
terized by complete liver necrosis associated with cardiovascular
shock, renal and respiratory failure.12 Yet, even in severe
acetaminophen-induced ALF, the liver damage usually resolves
spontaneously with appropriate treatment in up to 90% of cases,
with less than 10% requiring liver transplantation.4–6 In patients
who recover without OLT, there appears to be no long-lasting
liver damage.
It has been observed that in AOD-induced ALF patients, a
complete hepatectomy can lead to short-term reversal of unre-
sponsive shock.12–15 It has been postulated that a partial hepatec-
tomy may have similar effects if a large enough amount of the
‘toxic burden’ is removed. Further, as the liver injury is fully
reversible, implantation of a donor liver may allow temporary
support while the native liver remnant recovers.
There are three described techniques for auxiliary liver trans-
plantation (ALT): heterotopic auxiliary liver transplant (HALT),
auxiliary partial orthotopic liver transplant (APOLT) and whole
graft auxiliary transplant (WGALT). HALT involves leaving the
native liver in situ and placing a whole or split graft in a hetero-
topic position, but HALT has yielded poor results. APOLT
involves resection of a portion of liver and placement of a corre-
sponding split graft in an orthotopic manner. Results have gen-
erally been reasonable, although few patients have completely
ceased immunosuppression.16–21
Emergency transplantation outcomes are consistently poorer
than those of elective transplantation, with high early post-
transplant mortality, mainly as a result of sepsis, neurological
complications and multi-organ failure.1,6 Patients with
acetaminophen-induced ALF usually have a greater severity of
illness than seen in ALF from other causes and this is reflected in
a higher 30-day post-transplant mortality of around 25%.1,4,6 Our
1-year survival of 71% is equal to that of studies of OLT in AOD
induced ALF.4,5,8 Excellent long-term survival rates have been
achieved and there was only one late death at 23 months in a
patient with hepatitis C and alcoholism (67% patient survival,
63% native liver survival). Importantly, we have shown that after
transplantation, native regeneration is present in 100% of survi-
vors and liver function is restored, with all eligible patients off
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immunosuppression. Previous studies have shown that native
recovery does not occur in all cases of ALF, but this relates to
aetiology.16–18
A previous controversy relating to ALT was the functional
competition resulting from the portal blood flow shared by the
graft and the native liver.19–21 Various techniques have been
applied to overcome this problem, but in this series, we have not
observed any portal blood flow competition and we have
described the reasons for this previously.11 APOLT usually
involves a hemihepatectomy or less and has the disadvantage
over WGALT of leaving a greater amount of necrotic liver tissue.
In our WGALT the patient undergoes a right hepatic trisec-
tionectomy (removal of segments 4, 5, 6, 7 and 8) which corre-
sponds to greater than 70% of liver mass. Other advantages of
our technique include placement of a whole donor graft, ensur-
ing there is maximal liver volume to aid recovery. This avoids any
small for size problems potentially encountered in APOLT and
gives the patient the best chance of restoration of liver func-
tion.22,23 It also reduces the morbidity associated with two hepatic
transection surfaces such as bleeding and bile leaks.18 This series
is unique in that we have used WGALT exclusively for AOD ALF
and not for any other aetiology of acute liver failure. In AOD ALF
there is an excellent chance of native liver regeneration, and
therefore, a graft can truly bridge the gap between ALF and
native liver recovery/regeneration. It was found that donor age, a
requirement for a blood transfusion and recipient weight were
statistically significant factors related to survival. These have been
demonstrated in other previous studies.24–30 However, owing to a
small series it is difficult to draw real conclusions and therefore
form guidelines based on these findings.
We have had no problems with liver regeneration in our
patients: all have had good native liver remnant hypertrophy and
have normal liver function in the long term, except for the patient
who had established hepatitis C which progressed and was exac-
erbated by alcoholism. This study has demonstrated that during
the first few months post-operatively there is a need for intensive
monitoring of these patients. However, once the patient is off
immunosuppression, there is little or no follow-up required. It is
therefore likely that a subtotal hepatectomy with WGALT in the
setting of AOD is more cost effective in the long term than OLT.
There were also no problems with chronic renal impairment as
noted in the OLT group.
In summary, we advocate the technique of a right hepatic tri-
sectionectomy and whole graft auxiliary liver transplantation for
those patients who have acute acetominophen hepatotoxicity
requiring liver transplantation. We are pleased we have achieved
our goal of complete immunnosuppression withdrawal in all
patients where the auxiliary graft provided an effective bridge to
recovery. Although a prospective clinical trial now seems justified,
the complexity of this patient group means the widespread adop-
tion of this demanding surgical technique will not be achieved
unless physicians dealing with AOD-induced ALF recognize its
value.
Conflicts of interest
None declared.
References
1. Bernal W, Auzinger G, Dhawan A, Wendon J. (2010) Acute liver failure.
Lancet 376:190–201.
2. Stravitz RT, Kramer DJ. (2009) Management of acute liver failure. Nat Rev
Gastroenterol Hepatol 6:542–553.
3. Bernal W, Wendon J. (2000) Acute liver failure. Curr Opin Anaesthesiol
13:113–118.
4. Marudanayagam R, Shanmugam V, Gunson B, Mirza DF, Mayer D,
Buckels J et al. (2009) Aetiology and outcome of acute liver failure. HPB
11:429–434.
5. Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. (2009) Acetaminophen hepa-
totoxicity and acute liver failure. J Clin Gastroenterol 43:342–349.
6. Khan LR, Oniscu GC, Powell JJ. (2010) Long-term outcome following
liver transplantation for paracetamol overdose. Transpl Int 23:524–529.
7. Bernal W, Wendon J. (2004) Liver transplantation in adults with acute liver
failure. J Hepatol 40:192–197.
8. Cooper SC, Aldridge RC, Shah T, Webb K, Nightingale P, Paris S
et al. (2009) Outcomes of liver transplantation for paracetamol
(acetaminophen)-induced hepatic failure. Liver Transpl 15:1351–1357.
9. Halazun KJ, Al-Mukhtar A, Aldouri A, Malik HZ, Attia MS, Prasad KR et al.
(2007) Right hepatic trisectionectomy for hepatobiliary diseases: results
and an appraisal of its current role. Ann Surg 246:1065–1074.
10. Nishio H, Hidalgo E, Hamady ZZ, Ravindra KV, Kotru A, Dasgupta D et al.
(2005) Left hepatic trisectionectomy for hepatobiliary malignancy: results
and an appraisal of its current role. Ann Surg 242:267–275.
11. Lodge JP, Dasgupta D, Prasad KR, Attia M, Toogood GJ, Davies M
et al. (2008) Emergency subtotal hepatectomy: a new concept for
acetaminophen-induced acute liver failure: temporary hepatic support by
auxiliary orthotopic liver transplantation enables long-term success. Ann
Surg 247:238–249.
12. Ringe B, Lubbe N, Kuse E, Frei U, Pichlmayr R. (1993) Total hepatectomy
and liver transplantation as two-stage procedure. Ann Surg 218:3–9.
13. Dominguez Fernandez E, Lange K, Lange R, Eigler FW. (2001) Relevance
of two-stage total hepatectomy and liver transplantation in acute liver
failure and severe liver trauma. Transpl Int 14:184–190.
14. Oldhafer KJ, Bornscheuer A, Fruhauf NR, Frerker MK, Schlitt HJ, Ringe B
et al. (1999) Rescue hepatectomy for initial graft non-function after liver
transplantation. Transplantation 67:1024–1028.
15. Ferraz-Neto BH, Moraes-Junior JM, Hidalgo R, Zurstrassen MP, Lima IK,
Novais HS et al. (2008) Total hepatectomy and liver transplantation as a
two-stage procedure for toxic liver: case reports. Transplant Proc 40:814–
816.
16. Quaglia A, Portmann BC, Knisely AS, Srinivasan P, Muiesan P, Wendon
J et al. (2008) Auxiliary transplantation for acute liver failure: histopatho-
logical study of native liver regeneration. Liver Transpl 14:1437–1448.
17. van Hoek B, de Boer J, Boudjema K, Williams R, Corsmit O, Terpstra OT.
(1999) Auxiliary versus orthotopic liver transplantation for acute liver
failure. EURALT Study Group. European Auxiliary Liver Transplant Reg-
istry. J Hepatol 30:699–705.
18. Azoulay D, Samuel D, Ichai P, Castaing D, Saliba F, Adam R et al. (2001)
Auxiliary partial orthotopic versus standard orthotopic whole liver trans-
plantation for acute liver failure: a reappraisal from a single center by a
case-control study. Ann Surg 234:723–731.
19. Jaeck D, Pessaux P, Wolf P. (2007) Which types of graft to use in patients
with acute liver failure? (A) Auxiliary liver transplant (B) Living donor liver
HPB 227
HPB 2014, 16, 220–228 © 2013 International Hepato-Pancreato-Biliary Association
transplantation (C) The whole liver. (A) I prefer auxiliary liver transplant.
J Hepatol 46:570–573.
20. Broering DC, Walter J, Bassas AF. (2005) Overcoming the portal steal
phenomenon in auxiliary partial orthotopic liver transplantation by modu-
lation of the venous outflow of the native liver. Liver Transpl 11:1140–1143.
21. Kasahara M, Takada Y, Egawa H, Fujimoto Y, Ogura Y, Ogawa K et al.
(2005) Auxiliary partial orthotopic living donor liver transplantation: Kyoto
University experience. Am J Transplant 5:558–565.
22. Girlanda R, Vilca-Melendez H, Srinivasan P, Muiesan P, O'Grady JG, Rela
M et al. (2005) Immunosuppression withdrawal after auxiliary liver trans-
plantation for acute liver failure. Transplant Proc 37:1720–1721.
23. Heaton N. (2003) Small-for-size liver syndrome after auxiliary and split
liver transplantation: donor selection. Liver Transpl 9:S26–S28.
24. Wiederkehr JC, Igreja MR, Nogara MS, Goncalves NL, Wiederkehr BA,
Nascimento VB et al. (2010) Analysis of survival after primary liver trans-
plantation: multivariate analysis of 155 cases in a single center. Trans-
plant Proc 42:511–512.
25. Bontempo FA, Lewis JH, Van Thiel DH, Spero JA, Ragni MV, Butler
P et al. (1985) The relation of preoperative coagulation findings to
diagnosis, blood usage, and survival in adult liver transplantation. Trans-
plantation 39:532–536.
26. Ramos E, Dalmau A, Sabate A, Lama C, Llado L, Figueras J et al. (2003)
Intraoperative red blood cell transfusion in liver transplantation: influence
on patient outcome, prediction of requirements, and measures to reduce
them. Liver Transpl 9:1320–1327.
27. Cacciarelli TV, Keeffe EB, Moore DH, Burns W, Busque S, Concepcion W
et al. (1999) Effect of intraoperative blood transfusion on patient outcome
in hepatic transplantation. Arch Surg 134:25–29.
28. Cescon M, Vetrone G, Grazi GL, Ramacciato G, Ercolani G, Ravaioli M
et al. (2009) Trends in perioperative outcome after hepatic resection:
analysis of 1500 consecutive unselected cases over 20 years. Ann Surg
249:995–1002.
29. Macedo FI, Miranda LE, Fernandes JL, Padua TC, Figueroa JN, Neto OL
et al. (2010) Donor age as a predictor of risk for short-term outcomes
after liver transplant. Exp Clin Transplant 8:202–209.
30. Cassuto JR, Patel SA, Tsoulfas G, Orloff MS, Abt PL. (2008) The cumu-
lative effects of cold ischemic time and older donor age on liver graft
survival. J Surg Res 148:38–44.
228 HPB
HPB 2014, 16, 220–228 © 2013 International Hepato-Pancreato-Biliary Association
